CULVER CITY, Calif.–(BUSINESS WIRE)–NantKwest, Inc. (formerly Conkwest, Inc.) (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced today the closing of its initial public offering of 9,531,200 shares of common stock at a price to the public of $25.00 per share, which included 1,243,200 shares sold pursuant to the exercise in ful
Source:: feeds.businesswire.com/click.phdo?i=21ae3c448cb9c0e4fa1df12f89226164
Related posts:
Fantex Series Michael Brockers Convertible Tracking Stock Begins Trading at Fantex.com
Ligand Summarizes the Accounting Impact of the Viking Therapeutics, Inc. IPO and Updates 2015 Financial Guidance
Conkwest Files Registration Statement for Proposed Initial Public Offering
Digicel Files Registration Statement for Proposed Initial Public Offering
